Work

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mds511

Authors: V.M. Macaulay, M.R. Middleton, A.S. Protheroe, A. Tolcher, V. Dieras, C. Sessa, R. Bahleda, J.-Y. Blay, P. LoRusso, D. Mery-Mignard, J.-C. Soria

Institutions: Churchill Hospital, University of Oxford, South Texas Accelerated Research Therapeutics, Institut Curie, Ospedale San Giovanni Bellinzona, Istituto Oncologico della Svizzera Italiana, Institut Gustave Roussy, Centre Léon Bérard, The Barbara Ann Karmanos Cancer Institute, Sanofi (France)

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Sanofi, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research

OpenAlex ID: W2104906182

FWCI: 4.37

Cites: 46

Cited by: 51

Related to: 10